SCHEMBL30009212

SCHEMBL30009212

CCCS(=O)(=O)Nc1ccc(-c2ncnc3[nH]ccc23)cc1F

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 13/20 0.70
JAK1 P23458 4/20 0.60
AURKA O14965 1/20 0.56
DAPK3 O43293 1/20 0.56
JAK2 O60674 1/20 0.56
PRKD3 O94806 1/20 0.56
MAP4K4 O95819 1/20 0.56
PAK4 O96013 1/20 0.56
NTRK1 P04629 1/20 0.56
CSF1R P07333 1/20 0.56
RET P07949 1/20 0.56
IGF1R P08069 1/20 0.56
MET P08581 1/20 0.56
PIM1 P11309 1/20 0.56
FGFR1 P11362 1/20 0.56
PRKACA P17612 1/20 0.56
FLT1 P17948 1/20 0.56
LTK P29376 1/20 0.56
GRK5 P34947 1/20 0.56
KDR P35968 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30009826 0.93 JAK1 (0.63) KITJAK1AURKADAPK3JAK2
SCHEMBL30009847 0.86 KIT (0.66) KITJAK1AURKADAPK3JAK2
SCHEMBL30009359 0.83 JAK1 (0.56) KITJAK1ROCK1IKBKBCHUK
SCHEMBL15664873 0.83 KIT (1.00) KIT
SCHEMBL30009538 0.82 KIT (0.69) KITJAK1AURKADAPK3JAK2
SCHEMBL15665164 0.79 KIT (1.00) KITRETFGFR1FLT1KDR
SCHEMBL30010080 0.77 JAK1 (0.55) KITJAK1ROCK1IKBKBCHUK
SCHEMBL30009844 0.76 JAK1 (0.64) JAK1ROCK1IKBKBCHUK
SCHEMBL20918823 0.76 JAK1 (1.00) JAK1
SCHEMBL30009793 0.75 KIT (0.71) KITJAK1AURKADAPK3JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor HK INNO.N CORPORATION (KR) 2022-12-13 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11524968-B2 Heterocyclic compound as a protein kinase inhibitor MAP3K20, MAP3K15, MAP3K1 KIT 3668/4885JAK1 83/4885AURKA 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.